CRNX (Crinetics Pharmaceuticals) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 28, 2026)


CRNX Crinetics Pharmaceuticals Inc CRNX
47 GF Score
Price $36.64
GF Value $678.51
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Crinetics Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Crinetics Pharmaceuticals's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

CRNX vs ACAD, VKTX, EWTX: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Crinetics Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crinetics Pharmaceuticals Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Crinetics Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.


CRNX
47GF Score
Crinetics Pharmaceuticals Inc CRNX
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Crinetics Pharmaceuticals (CRNX) Overvalued in 2026?

Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued. The current stock price of $36.64 is trading 94.6% below its estimated GF Value™ of $678.51. GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.

Key valuation signals for CRNX:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $678.51 vs. price of $36.64 (94.6% below fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the CRNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Crinetics Pharmaceuticals Business Description

Other Exchanges 6Z4:Germany
Address 6055 Lusk Boulevard, San Diego, CA, USA, 92121
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
47GF Score

Get the complete analysis for CRNX

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.64
Price
$678.51
GF Value